We work with governments and organisations by providing solutions to control transboundary and emerging diseases, such as vaccine or antigen banks, emergency supply of vaccines, and raising disease awareness.

We continuously look for new ways to help animals and people. Technological advancements, improving communications and digital innovations help us to provide the best solutions.

MSD Animal Health operates in more than 140 countries, with a regional understanding enabling rapid responses to emergencies and changing disease landscapes. For example, our expertise and rapid deliveries of Lumpyvax™ vaccine helped countries in Europe manage the lumpy skin disease outbreaks.

Research is central to what we do, both within company and in collaboration with leading institutes and universities. By rapidly recognising emerging threats we developed vaccines for Bluetongue Serotype 8 (Bovilis® BTV8) and Schmallenberg Disease (Bovilis® SBV). We regularly develop new FMD strains in response to changing epidemiology.